Japan to start OTC sales of emergency contraceptive in February

Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.

Daiichi Sankyo announced on December 18 that it will launch over-the-counter sales of the emergency contraceptive pill Norlevo starting February 2 next year. Produced by Aska Pharmaceutical, the drug received approval from the health ministry in October for OTC availability, making it the first of its kind in Japan without requiring a prescription.

There are no age restrictions on purchasing Norlevo, allowing anyone to buy it. However, for safety, it must be taken under the supervision of a trained pharmacist. The pill is effective in preventing pregnancy in about 80% of cases when taken within 72 hours of intercourse. Its suggested retail price is ¥7,480 per pill.

This move aims to improve access to contraception, offering a new option for women's health management in the country. Key terms include pharmaceuticals, health, pregnancy, and birth control.

Relaterade artiklar

Bipartisan group of lawmakers and advocates at a press conference outside FDA building, advocating for tighter regulations on mail-order abortion pills.
Bild genererad av AI

Opinionsundersökning och högprofilerade fall driver tvåpartiell push för att se över regler för abortpiller via post

Rapporterad av AI Bild genererad av AI Faktagranskad

En ny nationell undersökning och en rad tvångsfall intensifierar kraven från republikanska lagstiftare, delstatens generalåklagare och förespråksgrupper för att FDA ska återinföra stramare skyddsåtgärder för abortläkemedel – ett tryck som kommer även när federala hälsomyndigheter säger att de granskar mifepristonens säkerhet och FDA har godkänt en andra generisk version.

Brazil's National Health Surveillance Agency (Anvisa) has approved lenacapavir, sold as Sunlenca, for use as pre-exposure prophylaxis (PrEP) against HIV-1. The drug, given via subcutaneous injection every six months, demonstrated up to 100% efficacy in clinical trials with vulnerable populations. The approval paves the way for regulatory steps that could lead to its availability in the Unified Health System (SUS).

Rapporterad av AI

Following the closure of local pharmacies on remote islands off Okinawa's main island, Sukoyaka pharmacy in Naha has begun dispensing medicines via video calls. This service now reaches residents on Minamidaito Island and Yonaguni Island, hundreds of kilometers away.

I den andra Trump-administrationen trycker Heritage Foundations forskare på hälsominister Robert F. Kennedy Jr. att beordra "guldstandard"-studier och utöka kraven på upplyst samtycke för orala preventivmedel, med argumentet att pillren medför underskattade hälsomässiga och ekologiska kostnader.

Rapporterad av AI

Japan's first female prime minister, Sanae Takaichi, is considering dissolving the lower house for a snap election in early February. According to the Yomiuri newspaper, the move aims to capitalize on her strong approval ratings since taking office in October. Her tough stance on China has appealed to right-wing voters but ignited a major diplomatic row with the Asian neighbor.

Following the fiscal 2026 budget's record ¥39.06 trillion allocation for social security, Japan's government has finalized two key reform measures to curb soaring medical costs, including higher patient copayments and limits on insurance for certain drugs. Officials emphasize the need for clear explanations to secure public understanding.

Rapporterad av AI

LY Corp., operator of Yahoo! Japan, has announced a ban on reselling new Mobile Suit Gundam plastic models and similar kits at prices above retail on its flea market and auction sites for three months after release. The policy aims to curb malicious high-price resales and hoarding. It will take effect on February 6.

 

 

 

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj